SCHEMBL23199577

SCHEMBL23199577

CC1(C)OB(c2cc(Cl)cc(CCNC(=O)O)c2)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
CNR1 P21554 2/20 0.39
LIPG Q9Y5X9 3/20 0.39
F11 P03951 2/20 0.37
F2 P00734 1/20 0.37
PRSS1 P07477 1/20 0.37
PRSS2 P07478 1/20 0.37
PRSS3 P35030 1/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
THRB P10828 1/20 0.36
LPL P06858 2/20 0.36
KMT2A Q03164 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2145222 0.81 LIPG (0.58) CA1CA2CA9LIPGL3MBTL1
SCHEMBL1684672 0.80 CA1 (0.61) CA1CA2CA9LIPGF11
SCHEMBL6691749 0.77 CNR1 (0.58) CNR1LMNAKDM4EL3MBTL1ALDH1A1
SCHEMBL25280776 0.76 HSP90AB1 (0.43) CA1CA2CA9LIPGF11
SCHEMBL30464569 0.76 HSP90AB1 (0.43) CA1CA2CA9LIPGF11
SCHEMBL138014 0.74 MAPT (0.39) LIPGF11LMNAKDM4ELPL
SCHEMBL16169739 0.73 PRMT5 (0.48) CA1CA2CA9LMNAKDM4E
SCHEMBL19376817 0.73 HPGD (0.41) CA1CA2CA9CNR1LMNA
SCHEMBL16444822 0.73 LIPG (0.52) CA1CA2CA9LIPGALDH1A1
SCHEMBL9888401 0.72 LIPG (0.58) CA1CA2CA9LIPGF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11046699-B2 Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses RAPT THERAPEUTICS, INC. (US) 2021-06-29 US disclosed
EP-3802544-A1 PYRAZOLO-PYRIMIDIN-AMINO-CYCLOALKYL COMPOUNDS AND THEIR THERAPEUTIC USES RAPT Therapeutics, Inc. (US) 2021-04-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046699-B2 Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses GLS, GLS2, TK2 CA1 4829/4885CA2 4097/4885CA9 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.